211 related articles for article (PubMed ID: 21824975)
1. Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.
Sroka IC; Sandoval CP; Chopra H; Gard JM; Pawar SC; Cress AE
Mol Cancer Res; 2011 Oct; 9(10):1319-28. PubMed ID: 21824975
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
3. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Zhang J; Sud S; Mizutani K; Gyetko MR; Pienta KJ
Neoplasia; 2011 Jan; 13(1):23-30. PubMed ID: 21245937
[TBL] [Abstract][Full Text] [Related]
4. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
5. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
Demetriou MC; Pennington ME; Nagle RB; Cress AE
Exp Cell Res; 2004 Apr; 294(2):550-8. PubMed ID: 15023541
[TBL] [Abstract][Full Text] [Related]
6. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Ahmed N; Riley C; Oliva K; Rice G; Quinn M
Br J Cancer; 2005 Apr; 92(8):1475-85. PubMed ID: 15798771
[TBL] [Abstract][Full Text] [Related]
7. Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
Kacsinta AD; Rubenstein CS; Sroka IC; Pawar S; Gard JM; Nagle RB; Cress AE
Biochem Biophys Res Commun; 2014 Nov; 454(2):335-40. PubMed ID: 25450398
[TBL] [Abstract][Full Text] [Related]
8. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
9. Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells.
Marconi C; Bianchini F; Mannini A; Mugnai G; Ruggieri S; Calorini L
Clin Exp Metastasis; 2008; 25(3):225-31. PubMed ID: 18071911
[TBL] [Abstract][Full Text] [Related]
10. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
12. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Schiller HB; Szekeres A; Binder BR; Stockinger H; Leksa V
Mol Biol Cell; 2009 Feb; 20(3):745-56. PubMed ID: 19037107
[TBL] [Abstract][Full Text] [Related]
13. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.
Farris SD; Hu JH; Krishnan R; Emery I; Chu T; Du L; Kremen M; Dichek HL; Gold E; Ramsey SA; Dichek DA
J Biol Chem; 2011 Jun; 286(25):22665-77. PubMed ID: 21536666
[TBL] [Abstract][Full Text] [Related]
16. The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.
Margheri F; Luciani C; Taddei ML; Giannoni E; Laurenzana A; Biagioni A; Chillà A; Chiarugi P; Fibbi G; Del Rosso M
Oncotarget; 2014 Mar; 5(6):1538-53. PubMed ID: 24681666
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration.
Ahmad A; Kong D; Sarkar SH; Wang Z; Banerjee S; Sarkar FH
J Cell Biochem; 2009 Jun; 107(3):516-27. PubMed ID: 19330806
[TBL] [Abstract][Full Text] [Related]
18. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
20. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]